Jill Macoska to Prostate-Specific Antigen
This is a "connection" page, showing publications Jill Macoska has written about Prostate-Specific Antigen.
Connection Strength
0.476
-
Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008 Mar 01; 68(4):442-52.
Score: 0.268
-
Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013 May; 73(6):573-81.
Score: 0.092
-
Kasina S, Macoska JA. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol. 2012 Apr 04; 351(2):249-63.
Score: 0.088
-
Sarma AV, Burke JP, Jacobson DJ, McGree ME, St Sauver J, Girman CJ, Lieber MM, Herman W, Macoska J, Montie JE, Jacobsen SJ. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men. Diabetes Care. 2008 Mar; 31(3):476-82.
Score: 0.016
-
Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL. LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate. 2003 Jun 01; 55(4):239-46.
Score: 0.012